Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008 Jan;10(1):10-7.
doi: 10.1007/s11912-008-0004-0.

The emerging role of lapatinib in HER2-positive breast cancer

Alice Ulhoa-Cintra  1 , Larisa Greenberg, Charles E Geyer
Affiliations
Review

The emerging role of lapatinib in HER2-positive breast cancer

Alice Ulhoa-Cintra et al. Curr Oncol Rep. 2008 Jan.

Abstract

In breast cancer, overexpression of HER2 is associated with an aggressive tumor phenotype and poor prognosis. Lapatinib has demonstrated benefit in combination with capecitabine in patients with HER2-positive locally advanced and metastatic breast cancer that has progressed after prior treatment with an anthracycline, a taxane, and trastuzumab. It has also demonstrated benefit with paclitaxel in patients with metastatic disease not previously treated with chemotherapy. This review discusses results from clinical trials suggesting an advantage with the use of lapatinib with other treatment modalities in the setting of metastatic and locally advanced disease.

PubMed Disclaimer

References

    1. Cancer Biol Ther. 2006 May;5(5):498-504 - PubMed
    1. J Clin Oncol. 2005 Aug 10;23(23):5305-13 - PubMed
    1. J Clin Oncol. 2002 Feb 1;20(3):719-26 - PubMed
    1. N Engl J Med. 2007 Jul 5;357(1):39-51 - PubMed
    1. J Clin Oncol. 2007 Jan 1;25(1):118-45 - PubMed

MeSH terms